Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of Choice for Stage I Non-small Cell Lung Cancer: Surgery or Radiotherapy?

Treatment of Choice for Stage I Non-small Cell Lung Cancer: Surgery or Radiotherapy? EDITORIAL Treatment of Choice for Stage I Non-small Cell Lung Cancer: Surgery or Radiotherapy? Hisao Asamura, MD he textbook description on the treatment of choice for stage I non-small cell lung Tcancer (NSCLC) has been surgery with or without adjuvant chemotherapy. In NSCLC, surgery still remains as a mainstay treatment that covers patients with stage I, II, and selected IIIA diseases. According to a recent report on a large Japanese contempo- raneous series of 6644 patients, the 5-year survival rates for resected stages IA and IB were 72.0 and 49.9% in a clinical setting and 79.5 and 60.1% in a pathological setting. The operative risk (morbidity and mortality) has also been minimized in the last few decades, probably because of adequate patient selection and evaluation. According to American patterns of surgical care study data, the overall mortality rate was reported at 5.2%, and rates of 3.2% for high-volume hospitals and 4.5% for lobectomy were also shown. Our recent institutional data in Tokyo also demonstrated an improved mortality rate at 0.5%, and this was closely related to the extent of pulmonary resection, in which a higher mortality rate was shown for pneumonectomy (3.9%) compared with lobectomy (0.3%). Because of the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Treatment of Choice for Stage I Non-small Cell Lung Cancer: Surgery or Radiotherapy?

Asamura, Hisao
Journal of Thoracic Oncology , Volume 1 (8) – Oct 1, 2006
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/treatment-of-choice-for-stage-i-non-small-cell-lung-cancer-colon-GXpOXoIKbf

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

EDITORIAL Treatment of Choice for Stage I Non-small Cell Lung Cancer: Surgery or Radiotherapy? Hisao Asamura, MD he textbook description on the treatment of choice for stage I non-small cell lung Tcancer (NSCLC) has been surgery with or without adjuvant chemotherapy. In NSCLC, surgery still remains as a mainstay treatment that covers patients with stage I, II, and selected IIIA diseases. According to a recent report on a large Japanese contempo- raneous series of 6644 patients, the 5-year survival rates for resected stages IA and IB were 72.0 and 49.9% in a clinical setting and 79.5 and 60.1% in a pathological setting. The operative risk (morbidity and mortality) has also been minimized in the last few decades, probably because of adequate patient selection and evaluation. According to American patterns of surgical care study data, the overall mortality rate was reported at 5.2%, and rates of 3.2% for high-volume hospitals and 4.5% for lobectomy were also shown. Our recent institutional data in Tokyo also demonstrated an improved mortality rate at 0.5%, and this was closely related to the extent of pulmonary resection, in which a higher mortality rate was shown for pneumonectomy (3.9%) compared with lobectomy (0.3%). Because of the

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Oct 1, 2006

There are no references for this article.